Josh Enomoto

Josh Enomoto

Brokering multi-million-dollar deals with some of the world’s biggest companies and providing in-depth marketing analyses, Josh Enomoto takes his firsthand knowledge of the corporate boardroom and delivers them across several media outlets. In addition to his work at InvestorPlace, Josh contributes content for Benzinga, TipRanks, EmergingGrowth and Blockster. He is also a guest expert at CGTN America.

While leaving no stone unturned regarding sector coverage, Josh has written extensively about cryptocurrencies. You can follow him on Blockster, a crypto-centric social media platform and on LinkedIn.

Recent Articles

Novavax Can Still Make Coronavirus Vaccines Great Again

While Pfizer and Moderna enjoy first-to-market advantage, the reality is that being first in a vaccine race isn’t always the best. Plus, Novavax’s distinct approach could make NVAX stock a strong dark horse.

Can the Gig Economy Continue to Support Adobe Stock?

Due to the work-from-home pivot, Adobe stock suddenly found itself remarkably relevant, but will 2021 shine brightly as well?

Why It’s Time to Rethink Social Capital Hedosophia Holdings II

With a housing boom contradicting the implication behind a once-in-a-century pandemic, IPOB stock has been a startling beneficiary. But can the good times go on indefinitely?

The 7 Worst Performing Stocks of 2020

Perhaps this year like no other has demonstrated the yin-yang effect of the market. While we’ve seen incredible winners, these companies represent the worst performing stocks of 2020.

XpresSpa Bears Might Need Their Own Immunization

Given the huge technical losses suffered by XSPA stock, it’s no wonder why so many are abandoning ship. However, XpresSpa also remains surprisingly relevant despite the vaccine development.